We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Invitrogen Launches 60 Division Arrested Cell Lines
Product News

Invitrogen Launches 60 Division Arrested Cell Lines

Invitrogen Launches 60 Division Arrested Cell Lines
Product News

Invitrogen Launches 60 Division Arrested Cell Lines


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Invitrogen Launches 60 Division Arrested Cell Lines"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Invitrogen Corporation launches the first suite of 60 division arrested cell lines for screening a broad range of therapeutic targets.

Generated through a proprietary treatment of dividing cells, division arrested cells do not require lengthy and laborious cell culture procedures to prepare live cells for screening assays. Division arrested cells may be plated and assayed within 24 hours of thawing, and cell numbers increase only marginally after plating, thereby removing the variability caused by cell division during the course of an assay and providing more consistent results.

Division arrested cells show agonist-induced responses virtually indistinguishable from that of dividing cells, and exhibit no toxicity or apparent changes in signal transduction, ensuring researchers obtain the correct pharmacological profile.

The collection includes a broad range of cell lines developed for functional cell-based assays of G-protein coupled receptors, nuclear hormone receptors and hERG. The cell lines are available in two configurations: 1 x 384-well plate assay kits (including detection reagents) for small scale screening or evaluation purposes, and 10 x 384-well-plate kits for small to large scale screening.

Invitrogen acquired division arrest technology last year through the acquisition of Sentigen Corporation. As part of the Sentigen transaction, Invitrogen owns the patent family which includes U.S. Patent No. 7,045,281 and Australian Patent No. 2003270073.

Advertisement